In one study, combination therapy with PBMCs or NK cells and trastuzumab has been shown to induce ADCC-mediated activity towards pancreatic cancer cell lines, which was proportional to their level of HER2 expression (20) and supports our data in showing the potential for combination regimens that utilize the power of NK cell-mediated ADCC. This evidence concerns the gene ERBB2 and pancreatic neoplasm.